ALVR AlloVir
- 0.797
- -0.003-0.36%
- 0.805
- +0.008+0.99%
About AlloVir Company
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Company Profile
Company Executives
- Name
- Position
- Salary
- Dr. Diana M. Brainard, M.D.
- Chief Executive Officer and Director
- 9.21M
- Vikas Sinha
- Principal Accounting Officer, Director, President and Chief Financial Officer
- 2.90M
- Dr. Ann Leen, PhD
- Chief Scientific Officer
- --
- David L. Hallal
- Executive Chairman of the Board
- 347.40K
- Dr. Juan Vera, M.D.
- Director
- 133.03K
- Shawn Cline Tomasello, M.B.A.
- Independent Director
- 399.10K
- Jeffrey S. Bornstein
- Independent Director
- 153.03K
- Dr. Ansbert S. Gadicke,M.D.,PhD
- Independent Director
- 146.62K
- Dr. Morana Jovan-Embiricos, PhD
- Independent Director
- 150.53K
- Dr. Malcolm Brenner, M.D.
- Independent Director
- 97.07K
- Dr. Derek N. Ada PhD
- Independent Director
- --
- Edward Miller
- General Counsel and Secretary
- 1.48M
Analysis
Price Target
No Data
